Bruker Co. (BRKR) Receives $33.11 Consensus PT from Analysts
Bruker Co. (NASDAQ:BRKR) has been given a consensus rating of “Hold” by the twelve analysts that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $33.11.
Several equities analysts have weighed in on BRKR shares. ValuEngine raised Bruker from a “sell” rating to a “hold” rating in a research note on Thursday, July 19th. Zacks Investment Research downgraded Bruker from a “hold” rating to a “sell” rating in a report on Tuesday, July 24th. BidaskClub upgraded Bruker from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 25th. Finally, Morgan Stanley increased their price target on Bruker from $29.00 to $31.00 and gave the stock an “equal weight” rating in a report on Friday, August 3rd.
Several large investors have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in shares of Bruker by 1.7% during the second quarter. BlackRock Inc. now owns 5,358,747 shares of the medical research company’s stock worth $155,618,000 after buying an additional 91,058 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Bruker by 1.3% during the first quarter. Russell Investments Group Ltd. now owns 1,483,860 shares of the medical research company’s stock worth $44,397,000 after buying an additional 19,226 shares in the last quarter. Boston Partners grew its holdings in shares of Bruker by 2.7% during the first quarter. Boston Partners now owns 1,297,471 shares of the medical research company’s stock worth $38,821,000 after buying an additional 34,578 shares in the last quarter. Millennium Management LLC boosted its position in Bruker by 15.2% during the second quarter. Millennium Management LLC now owns 1,279,814 shares of the medical research company’s stock valued at $37,166,000 after purchasing an additional 168,597 shares during the last quarter. Finally, Epoch Investment Partners Inc. acquired a new position in Bruker during the second quarter valued at approximately $32,708,000. Institutional investors and hedge funds own 65.61% of the company’s stock.
Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, August 2nd. The medical research company reported $0.25 earnings per share for the quarter, meeting the consensus estimate of $0.25. Bruker had a return on equity of 27.03% and a net margin of 4.99%. The firm had revenue of $443.70 million for the quarter, compared to analyst estimates of $436.10 million. During the same quarter in the prior year, the firm posted $0.23 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. sell-side analysts predict that Bruker will post 1.38 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 21st. Shareholders of record on Tuesday, September 4th will be issued a $0.04 dividend. The ex-dividend date of this dividend is Friday, August 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.45%. Bruker’s dividend payout ratio (DPR) is currently 13.22%.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.